Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05876416

Decoding the Genetic Landscape of Skeletal Diseases

This 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders (GSDs); (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different GSD groups. For patients with unsolved GSD, the investigators search for molecular causes of GSDs using whole genome sequencing (WGS) and total ribonucleic acid (RNA) sequencing. Candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. Causality of the new variants is studied in cells and in transgenic mice models. Molecular and clinical findings are summarized for different GSD groups.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Genetic skeletal disorders (GSDs) are a large group of rare diseases caused by abnormalities in genes regulating skeletal development. This 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders; (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different GSD groups. The project is a collaboration between the Dept of Clinical Genetics, Karolinska University Hospital, Lab of Clinical Genetics and Lab of Bone and Cartilage Physiology, Karolinska Institutet and Sahlgrenska Academy. In a well-characterized group of 300 GSD participants whose DNA samples were analyzed using whole genome sequencing (WGS), there are 120 study participants with unsolved diagnoses. For those participants, we search for molecular causes of GSDs using WGS and total RNA sequencing. Candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. Causality of the new variants is studied in cells and in transgenic mice models. Molecular and clinical findings are summarized for different GSD groups. Our results improve diagnostics for GSDs, advance knowledge on pathogenesis and help establishing new individual follow-up and treatment strategies for patients with GSDs. This project increases understanding of skeletal pathophysiology and will contribute to the development of novel treatment methods for skeletal diseases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinically suspected skeletal dysplasia based on previous investigations

Abnormal height

Radiographic abnormalities of the skeleton in addition to other syndromic features

Healthy relatives of the affected study participants

Exclusion criteria

No radiographic data available from clinical investigations

Suspected environmental or multifactorial causes

Treatment and study plan

Primary outcomes

  1. New gene discoveries for genetic skeletal disorders (GSDs)

    Time frame: 2023-2028

    2-3 new disease causes and disease entities identified and reported per year for GSDs.

  2. Improved knowledge regarding natural cause of rare GSDs

    Time frame: 2023-2028

    1-2 GSDs reported as small patient groups with the same condition and clinical characteristics/course.

Secondary outcomes

  1. Disease (GSD) associated traits and complications

    Time frame: 2023-2028

    The observations include internal malformations, metabolic, biochemical and growth parameters, and secondary complications.

  2. Information on disease causing variants in GSD

    Time frame: 2023-2028

    During the study we identify several novel disease causing variants in known GSD genes and report them to databases.

Study contacts

Contact information is provided by the study sponsor or research team.

Giedre Grigelioniene, MD, PhD

CONTACT

[email protected]

+46706287697

Hillevi Lindelöf, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Göteborg University
  • Karolinska University Hospital

Registry information

Acronym: SKDLAND

Important dates

Study start
2015
Primary completion
2026
Study completion
2026
First posted
May 25, 2023
Registry last updated
May 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.